The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials
Open accessAbstract
CONTEXT: Plasma concentrations of the vasoconstrictor peptide endothelin-1 are increased in patients with heart failure, and higher concentrations are associated with worse outcomes. Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemodynamic actions in heart failure. OBJECTIVE: To determine if tezosentan improves outcomes in patients with acute heart failure. DESIGN, SETTING, AND PARTICIPANTS: The Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies, 2 independent, identical, and concurrent randomized, double-blind, placebo-controlled, parallel-group trials conducted from April 2003 through January 2005 at sites in Australia, Europe, Israel, and North America. Patients admitted within the previous 24 hours with persisting dyspnea and a respiratory rate of 24/min or greater were eligible provided they fulfilled 2 of 4 criteria: (1) elevated plasma concentrations of B-type or N-terminal pro-B-type natriuretic peptide, (2) clinical pulmonary edema, (3) radiologic pulmonary congestion or edema, or (4) left ventricular systolic dysfunction. INTERVENTION: Infusion of tezosentan (5 mg/h for 30 minutes, followed by 1 mg/h for 24 to 72 hours [n = 730]) or placebo (n = 718). MAIN OUTCOME MEASURES: The coprimary end points were change in dyspnea (measured at 3, 6, and 24 hours using a visual analog scale from 0-100) over 24 hours (as area under the curve) in the individual trials and incidence of death or worsening heart failure at 7 days in both trials combined. RESULTS: Of the 1435 patients who received treatment as assigned, 855 (60%) were men; mean age was 70 years. Mean left ventricular ejection fraction (measured in 779 patients [54%]) was 29% (SD, 11%). Baseline dyspnea scores were similar in the 2 treatment groups. Tezosentan did not improve dyspnea more than placebo in either trial, with a mean treatment difference of -12 (95% confidence interval [CI], -105 to 81) mm . h (P = .80) in the first trial and -25 (95% CI, -119 to 69) mm x h (P = .60) in the second. The incidence of death or worsening heart failure at 7 days in the combined trials was 26% in each treatment group (odds ratio, 0.99; 95% confidence interval, 0.82-1.21; P = .95). CONCLUSION: The endothelin receptor antagonist tezosentan did not improve symptoms or clinical outcomes in patients with acute heart failure. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: NCT00525707 (VERITAS-1) and NCT00524433 (VERITAS-2).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endorsed by the European Society of Intensive Care Medicine (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi044 · Cited by 1,178
Cuffe, M. S. (2002) · JAMA · doi:10.1001/jama.287.12.1541 · Cited by 1,175
(2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00795-x · Cited by 980
Colucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L. E., Givertz, M. M., Liang, C.-S., Neibaur, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430403 · Cited by 911
Self-citationSackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D. (2005) · Circulation · doi:10.1161/01.cir.0000159340.93220.e4 · Cited by 765
Acute Heart Failure Syndromes: Current State and Framework for Future Research
Gheorghiade, M., Zannad, F., Sopko, G., Klein, L., Piña, I. L., Konstam, M. A., Massie, B. M., Roland, E., Targum, S., Collins, S. P., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.590091 · Cited by 763
Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K. (2005) · JAMA · doi:10.1001/jama.293.15.1900 · Cited by 693
Moiseyev, V (2002) · European Heart Journal · doi:10.1053/euhj.2001.3158 · Cited by 595
Cited by
Konstam, M. A., Kiernan, M. S., Bernstein, D., Bozkurt, B., Jacob, M., Kapur, N. K., Kociol, R. D., Lewis, E. F., Mehra, M. R., Pagani, F. D., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000560 · Cited by 945
Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., Ponikowski, P., Unemori, E., Voors, A. A., Adams, K. F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61855-8 · Cited by 918
Self-citationStructured telephone support or telemonitoring programmes for patients with chronic heart failure
Inglis, S. C., Clark, R. A., McAlister, F. A., Ball, J., Lewinter, C., Cullington, D., Stewart, S., & Cleland, J. G. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007228.pub2 · Cited by 614
Self-citationGheorghiade, M., & Pang, P. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.041 · Cited by 600
Endothelial Dysfunction, Arterial Stiffness, and Heart Failure
Marti, C. N., Gheorghiade, M., Kalogeropoulos, A. P., Georgiopoulou, V. V., Quyyumi, A. A., & Butler, J. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.082 · Cited by 488
Metadata
- Authors
- McMurray, J. J. V., Teerlink, J. R., Cotter, G., Bourge, R. C., Cleland, J. G. F., Jondeau, G., Krum, H., Metra, M., O’Connor, C. M., Parker, J. D., Torre-Amione, G., van Veldhuisen, D. J., Lewsey, J., Frey, A., Rainisio, M., Kobrin, I., & VERITAS Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-11-07
- Volume
- 298
- Issue
- 17
- Pages
- 2009
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2168017932
- Cited by
- 360
- References
- 29
- FWCI
- 17.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials. https://app.cochat.ai/papers/10.1001/jama.298.17.2009
- The paper
- McMurray, J. J. V., Teerlink, J. R., Cotter, G., Bourge, R. C., Cleland, J. G. F., Jondeau, G., Krum, H., Metra, M., O’Connor, C. M., Parker, J. D., Torre-Amione, G., van Veldhuisen, D. J., Lewsey, J., Frey, A., Rainisio, M., Kobrin, I., & VERITAS Investigators, F. T. (2007). Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure: The VERITAS Randomized Controlled Trials. JAMA. https://doi.org/10.1001/jama.298.17.2009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.